Clinical Trial Update: Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia [Phase 1]

View source ↗

Summary

Phase I study evaluating bevacizumab plus sorafenib with low-dose cyclophosphamide in patients with refractory solid tumors and leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Solid Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cytoxan (cyclophosphamide)
• Sorafenib (Sorafenib)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Refractory Solid Tumors, Leukemia | Phase 1 | Status: COMPLETED